

30th Annual South Florida Residency Seminar

Thirty Years of CE Pearls

January 31 and Feb 1, 2026

32 total Live Hours Continuing Education Credit for
General Pharmacist & Technician as well as Consulting Recertification
Track 1 20-1342082; Track 2 20-1342097; Controlled Substance Val 20-1342065
(**Note: Participants wishing Consultant Recertification MUST attend the
final 3 hours on Track 1 to obtain full 12hr RCE credit**).

TRACK 1: - Saturday, January 31, 2026

Title of Presentation: Validating Controlled Substances Prescriptions.

Name(s) of Presenter(s) Erwin Lanzas, Jeanna Harding, Kyle Eilert, Gladimarys Grajales

Goal/Objective 1: Discuss the laws and regulations related to the prescribing, assessing the validity of, and dispensing of controlled substances

Goal/Objective 2: Analyze pharmacist's responsibility and judgment in determining appropriateness of controlled substance prescriptions and ensuring access to pain care.

Goal/Objective 3: Review the role and appropriateness of opioids in the treatment of acute and chronic pain management.

Goal/Objective 4: Identify methods for validating controlled substance prescriptions and review strategies for distinguishing invalid prescriptions based on legitimate medical purpose.

Goal/Objective 5: Review Florida's Prescription Drug Monitoring Program's Database (PDMP).

Goal/Objective 6: Understand the premise of emergency filling, partial filling of controlled substances.

Goal/Objective 7: Review patient counseling points for controlled substances including adverse effects, drug interactions, storage conditions and disposal.

Goal/Objective 8: Explain the use of naloxone for the emergency treatment of suspected drug overdose and review the treatment resources for opioid physical dependence, addiction, misuse, and abuse.

Goal/Objective 9: Provide or offer to provide available resources for treatment of opioid physical dependence, addiction, misuse or abuse.

Title of Presentation: The Update on the Fuzz: Antifungal Treatment Update.

Name(s) of Presenter(s) David Alirezaei

Goal/Objective 1: Describe major classes of clinically relevant fungi and their associated infections

Goal/Objective 2: Summarize FDA-approved antifungal agents, including their mechanisms of action, spectra of activity, and key adverse effects

Goal/Objective 3: Identify antifungal agents that require therapeutic drug monitoring and outline basic monitoring parameters

Goal/Objective 4: Review novel antifungal agents in development and their potential therapeutic roles

Title of Presentation: Don't Hold it! – UTI Treatment Update.

Name(s) of Presenter(s) Gabriela Urreta

Goal/Objective 1: Review updated classification of uncomplicated versus complicated urinary tract infections

Goal/Objective 2: Discuss recommended empiric and definitive treatment of urinary tract infections

Goal/Objective 3: Describe recommended intravenous to oral transition timing and duration of antibiotic therapy

Title of Presentation: Til You're Blue in the Face! - HAP/CAP Treatment Guideline Update.

Name(s) of Presenter(s) Margarita Bellon

Goal/Objective 1: Review the pathophysiology, etiology, and diagnostic criteria of pneumonia

Goal/Objective 2: Describe guideline-directed empiric and definitive antimicrobial treatment regimens for pneumonia

Goal/Objective 3: Discuss recommendations for duration of therapy in accordance with guidelines updates

Title of Presentation: The Great Debate: GLP-1: which is better?

Name(s) of Presenter(s) Angel Villar

Goal/Objective 1: Describe the mechanism of action, pharmacokinetics, and safety profiles of currently available GLP-1: receptor agonists

Goal/Objective 2: Compare and contrast the efficacy of GLP-1: receptor agonists based on key clinical outcomes (e.g., glycemic control, weight loss, cardiovascular and renal benefits)

Goal/Objective 3: Evaluate patient specific factors (e.g., comorbidities, tolerability, administration frequency, insurance coverage) when selecting an appropriate GLP-1: receptor agonist

Goal/Objective 4: Apply evidence based clinical guidelines and landmark trials to optimize GLP-1: receptor agonist therapy in patient cases

Title of Presentation: Well, it's been a while Long term use of GLP-1.

Name(s) of Presenter(s) Alondra Santiago Diaz, PharmD

Goal/Objective 1: Describe the mechanism of action and pharmacologic differences among GLP-1: receptor agonists.

Goal/Objective 2: Evaluate clinical outcomes and evidence supporting the efficacy of GLP-1: receptor agonists.

Goal/Objective 3: Identify potential long-term adverse effects and safety considerations associated with GLP-1: receptor agonists use.

Goal/Objective 4: Discuss clinical guidelines supporting the use of GLP-1: receptor agonists in practice.

Title of Presentation: I found it on the internet GLP-1: Wellness Clinic Compounding.

Name(s) of Presenter(s) Rosemarie Ruiz Reyes

Goal/Objective 1: Define the FDA-approved indications, mechanisms of action, and pharmacokinetic properties of GLP-1: receptor agonists, including differences between branded and compounded formulations.

Goal/Objective 2: Explain the regulatory requirements and risks associated with online marketing and compounding GLP-1: receptor agonists.

Goal/Objective 3: Recognize common safety concerns and adverse events linked to compounded GLP-1: receptor agonists from online sources.

Goal/Objective 4: Apply evidence-based strategies for Pharmacist counseling and risk mitigation in patients using GLP-1: receptor agonists.

TRACK 1: - Sunday, February 1, 2026

Title of Presentation: What a Pair: Breast Cancer Treatment Updates.

Name(s) of Presenter(s) Vivian Rodriguez, PharmD

Goal/Objective 1: Explain the epidemiology, pathophysiology, clinical presentation, diagnosis, and risk factors of breast cancer.

Goal/Objective 2: Summarize the clinical guideline recommendations regarding the current treatment of advanced metastatic breast cancer in inpatient and outpatient settings.

Goal/Objective 3: Assess current specialty oral oncolytic therapies for advanced/metastatic breast cancer.

Goal/Objective 4: Evaluate novel oral oncolytics and emerging agents under development for advanced/metastatic breast cancer.

Title of Presentation: The Scoop on the Poop: Update on Colon Cancer Screening and Treatment.

Name(s) of Presenter(s) Christian Hu

Goal/Objective 1: Educate the audience on updates regarding the screening of colon cancer

Goal/Objective 2: Educate the audience on the updates regarding the treatment of colon cancer

Goal/Objective 3: Address any questions that the audience may have regarding colon cancer

Title of Presentation: Liver Cirrhosis and Split Liver Transplant.

Name(s) of Presenter(s) Julia Hetzel

Goal/Objective 1: Explain the concept of split liver transplantation and discuss the indications that warrant its use

Goal/Objective 2: Evaluate emerging research in split liver transplantation

Goal/Objective 3: Identify advantages and challenges associated with split liver transplantation

Goal/Objective 4: Review immunosuppression regimens for liver transplantation

Title of Presentation: Little Lungs – Asthma Treatment Update.

Name(s) of Presenter(s) MacKenzie Gaitens

Goal/Objective 1: Discuss the pathophysiology and inflammatory mediators of asthma.

Goal/Objective 2: Explain the treatment strategies of asthma.

Goal/Objective 3: Review asthma phenotypes and their unique clinical presentations.

Goal/Objective 4: Evaluate the role of currently available biologic therapies.

Goal/Objective 5: Identify patients who are candidates for biologic therapy based on phenotype and biomarkers

Title of Presentation: Multiplicity Versus Duplicity – “How many is too many?”

Name(s) of Presenter(s) Jennifer Magloire

Goal/Objective 1: Define multiplicity and duplicity in the context of biologic therapy.

Goal/Objective 2: Describe clinical and economic risks associated with inappropriate biologic use.

Goal/Objective 3: Apply guideline recommendations to evaluate appropriate use of biologics.

Goal/Objective 4: Analyze case scenarios to determine when biologic therapy represents “too many.”

Goal/Objective 5: Develop strategies to prevent and resolve issues of duplicity or multiplicity in clinical practice.

Title of Presentation: Don’t Leave Me Hanging! - Pediatric Vaccine Updates

Name(s) of Presenter(s) Shanda Nehemie Badette

Goal/Objective 1: Review recent updates to the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP) immunization schedules for children and adolescents.

Goal/Objective 2: Differentiate between routine, catch-up, and special population pediatric vaccine recommendations to optimize patient care.

Goal/Objective 3: Identify common barriers to pediatric vaccinations and discuss effective pharmacist-driven strategies to overcome them.

Goal/Objective 4: Incorporate best practices for vaccine administration, storage/handling, and documentation to ensure compliance with state laws and uphold patient safety.

Title of Presentation: RU Serious or JK? - Current State of Vaccine Guidelines.

Name(s) of Presenter(s) Hardik (Kanu) Maini

Goal/objective 1: Review the current landscape of vaccine recommendations and schedules

Goal/Objective 2: Summarize the most recent updates to vaccine recommendations from the Advisory Committee on Immunization Practices (ACIP)

Goal/Objective 3: Identify ongoing challenges and opportunities in vaccine Implementation and coverage.

Goal/Objective 4: Outline future directions and priorities for vaccine policy and Practice.

Title of Presentation: The Nations and Disease Outbreaks – To V or not to V

Name(s) of Presenter(s) Jay Blake, Milouse Dornevil

Goal/Objective 1: Describe the counter vaccine mis- and disinformation and increase public support for the individual and societal benefits of vaccination.

Goal/Objective 2: Support the development of innovative, safe, and effective vaccines to prevent infectious diseases of public health significance.

Goal/Objective 3: Define the pharmacist's role in educating patients and expanding vaccination rates

TRACK 2: - Saturday, January 3, 2026

Title of Presentation: Validating Controlled Substances Prescriptions

Name(s) of Presenter(s) Erwin Lanzas, Jeanna Harding, Kyle Eilert, Gladimarys Grajales

Goal/Objective 1: Discuss the laws and regulations related to the prescribing and dispensing of controlled substances

Goal/Objective 2: Analyze pharmacist's responsibility and judgment in determining appropriateness of controlled substance.

Goal/Objective 3: Review the role and appropriateness of opioids in the treatment of acute and chronic pain management.

Goal/Objective 4: Identify methods for validating controlled substance prescriptions and review strategies for distinguishing invalid prescriptions

Goal/Objective 5: Review Florida's Prescription Drug Monitoring Program's Database (PDMP).

Goal/Objective 6: Understand the premise of emergency filling of controlled substances.

Goal/Objective 7: Understand the premise of partial filling controlled substances.

Goal/Objective 8: Review patient counseling points for controlled substances including adverse effects, drug interactions, storage conditions and disposal.

Goal/Objective 9: Explain the use of naloxone for the emergency treatment of suspected drug overdose and review the treatment resources for opioid physical dependence, addiction, misuse, and abuse.

Title of Presentation: Well folks -It's Finally Here! You Must Comply – 797 Update

Name(s) of Presenter(s) Kassandra Rubi and Pooja Patel

Goal/Objective 1: Identify key changes in the 2023 USP 797 revision

Goal/Objective 2: Explain the updated risk categories

Goal/Objective 3: Discuss the revised requirements for personnel training, garbing, and competency assessment

Title of Presentation: ChatGPT or Me?: AI and Data-Driven Clinical Pathways

Name(s) of Presenter(s) Austin Torres, PharmD/ Niyaz Pordel, PharmD

Goal/Objective 1: Identify common applications of artificial intelligence (AI) tools in pharmacy and healthcare settings.

Goal/Objective 2: Evaluate the benefits and limitations of AI-driven tools (e.g., ChatGPT) in pharmacy practice and clinical decision-making.

Goal/Objective 3: Explain how AI platforms like ChatGPT can support clinical decision-making and streamline pharmacy workflows.

Goal/Objective 4: Compare traditional clinical pathways with data-driven approaches supported by AI technologies.

Goal/Objective 5: Discuss real-world examples of AI used in clinical pathways and how it compares to traditional pharmacist-led care.

Goal/Objective 6: Recognize potential risks, limitations, HIPPA violations and ethical considerations when integrating AI into healthcare systems.

Goal/Objective 7: Discuss ethical considerations, patient safety concerns, and pharmacist responsibilities when integrating AI into healthcare systems.

Title of Presentation: The Devil wears Prada: The Pressure Cooker- PBM.

Name(s) of Presenter(s) Faisal Alnefaie

Goal/Objective 1: Define the role and structure of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system.

Goal/Objective 2: Describe the key functions and mechanisms through which PBMs influence drug pricing, formulary management, and patient access to medications.

Goal/Objective 3: Describe the key functions and mechanisms through which PBMs influence drug pricing, formulary management, and patient access to medications.

Goal/Objective 4: Evaluate current regulatory efforts and reform proposals aimed at increasing PBM transparency and accountability.

Title of Presentation: The Joints are Aching: Rheumatoid Arthritis Treatment.

Name(s) of Presenter(s) Natalia N. Rivera Cruz, PharmD.

Goal/Objective 1: Describe key updates in the latest rheumatoid arthritis guidelines.

Goal/Objective 2: Apply evidence-based recommendations to patient- specific cases.

Goal/Objective 3: Incorporate strategies that improve therapeutic outcomes and long-term care

Goal/Objective 4: Enhance patient outcomes by selecting, monitoring, and collaborating on appropriate therapies.

Title of Presentation: Dermatologic Update: The Skin You're In.

Name(s) of Presenter(s) Janiel Tulloch

Goal/Objective 1: Discuss the role of biologics in dermatology

Goal/Objective 2: Discuss the role of the interdisciplinary team in biologic therapy in dermatology

Goal/Objective 3: Review FDA approved biologics for dermatologic conditions

Goal/Objective 4: Discuss challenges and limitations of biologics use in dermatology

Goal/Objective 5: Discuss emerging biologic therapies in dermatology

Title of Presentation: Making a Run for It!: Ulcerative Colitis and Crohn's Disease Treatment.

Name(s) of Presenter(s) Abdulaziz Salamatullah AND Ramon Moreno

Goal/Objective 1: Identify pathophysiology of Crohn's disease (CD)

Goal/Objective 2: List risk factors and causes of CD

Goal/Objective 3: Explain diagnosis of CD

Goal/Objective 4: Analyze current guidelines to develop appropriate regimen

TRACK 2: - Sunday, February 1, 2026

Title of Presentation: Huff and Puff: Update on Lung Cancer.

Name(s) of Presenter(s) Kyrlehn Galiotte

Goal/Objective 1: Provide an overview of the evolving landscape of lung cancer diagnosis and treatment

Goal/Objective 2: Discuss recent advances in lung cancer screening and early detection

Goal/Objective 3: Analyze recent advancements in systemic therapies including immunotherapy and targeted agents

Goal/Objective 4: Identify ongoing challenges and future directions in lung cancer research and treatment

Title of Presentation: From Lysis to Crisis: Navigating Oncologic Emergencies.

Name(s) of Presenter(s) Carlos Soto Gonzalez

Goal/Objective 1: Describe the risk factors, pathophysiology, and clinical presentation of tumor lysis syndrome, febrile neutropenia, and hypercalcemia of malignancy

Goal/Objective 2: Apply diagnostic criteria and evidence-based pharmacologic strategies to optimize the management of oncologic emergencies

Goal/Objective 3: Define the pharmacist's role in prevention and treatment of select oncologic emergencies

Title of Presentation: Back to Living out Loud: Migraine Treatment Update.

Name(s) of Presenter(s) Fabiola Plaza Vazquez

Goal/Objective 1: Review recent advances in acute and preventive migraine therapies, including novel pharmacologic agents and non-pharmacologic options.

Goal/Objective 2: Summarize updated clinical guidelines and consensus statements for migraine management from leading societies, highlighting changes in recommended treatment algorithms.

Goal/Objective 3: Discuss strategies for individualized, patient-centered care in migraine, emphasizing shared decision-making and tailoring therapy to comorbidities and patient preferences.

Goal/Objective 4: Explore future directions and emerging therapies in migraine management, addressing ongoing challenges and unmet needs in clinical practice.

Title of Presentation: If you See Something/Say Something: Early Detection is Key - Update on Alzheimer's Treatment.

Name(s) of Presenter(s) Riley Christian

Goal/Objective 1: Review the pathophysiology and progression of Alzheimer's disease, with an emphasis on early clinical signs and diagnostic criteria.

Goal/Objective 2: Discuss the importance of early detection and intervention in Alzheimer's disease, including its impact on patient outcomes and caregiver burden.

Goal/Objective 3: Evaluate current and emerging pharmacologic treatments for Alzheimer's disease, focusing on mechanisms of action, clinical efficacy, and safety profiles.

Goal/Objective 4: Describe recent updates in clinical guidelines and consensus recommendations for the treatment of Alzheimer's disease.

Goal/Objective 5: Identify the pharmacist's role in recognizing early symptoms, facilitating diagnosis, and optimizing treatment strategies in collaboration with the healthcare team.

Title of Presentation: The Calm Before the Storm: Update on Seizure Treatments.

Name(s) of Presenter(s) Maricela Moreno Martinez

Goal/Objective 1: Review recent updates in the management and treatment of seizure disorders

Goal/Objective 2: Recognize newly approved antiseizure medications and their clinical roles

Goal/Objective 3: Discuss current guideline recommendations and evidence – based treatment approaches

Goal/Objective 4: Apply updated treatment strategies and clinical pearls to optimize patient outcomes

Title of Presentation: Paging MaryJane! What's Up in the USA?: Recreational versus Medical versus Illegal.

Name(s) of Presenter(s) Lilia Jimenez

Goal/Objective 1: Differentiate between recreational, medical, and illegal cannabis use in the United States.

Goal/Objective 2: Summarize current federal and state laws regarding cannabis.

Goal/Objective 3: Evaluate the clinical and public health implications of medical vs recreational cannabis use.

Goal/Objective 4: Discuss challenges for healthcare professionals in navigating patient care and stigma related to cannabis use.

Title of Presentation: Now We Are Stuck With It!: The Need for Guidelines.

Name(s) of Presenter(s) Claudia Hechavarria Ramirez

Goal/Objective 1: Describe the pharmacology of cannabis, including available formulations and proposed mechanism of action.

Goal/Objective 2: Review current literature on medical cannabis use.

Goal/Objective 3: Discuss the legal and regulatory landscape of medical cannabis.

Goal/Objective 4: Explore patient access and key considerations for healthcare providers.

Title of Presentation: The Chicken or the Egg: Increased Risk Factors for Marijuana Use.

Name(s) of Presenter(s) Aitana Valdes Alsina

Goal/Objective 1: Analyze epidemiologic data to compare patterns of marijuana use across age groups.

Goal/Objective 2: Differentiate major risk factors that contribute to marijuana initiation and progression to misuse.

Goal/Objective 3: Evaluate the bidirectional associations between marijuana use and comorbid conditions.

Goal/Objective 4: Apply counseling strategies to optimize pharmacist-led interventions for patients at risk of problematic marijuana use.